The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIntertek Group Regulatory News (ITRK)

Share Price Information for Intertek Group (ITRK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 4,950.00
Bid: 4,976.00
Ask: 4,980.00
Change: -40.00 (-0.80%)
Spread: 4.00 (0.08%)
Open: 4,996.00
High: 5,015.00
Low: 4,950.00
Prev. Close: 4,990.00
ITRK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Acquisition

3 Aug 2018 07:00

RNS Number : 7100W
Intertek Group PLC
03 August 2018
 

 

3 August 2018, 7.00 am London, UK

 

 

Intertek expands its global Assurance business with the acquisition of Alchemy,

a leading provider of SaaS-based People Assurance solutions

Transaction highlights

- Industry-leading People Assurance content and technology platforms

- Attractive business model: high growth, high margin, strongly cash-generative, capital light and scalable

- Strong management team joining Intertek

- Transaction consideration: US$480m financed using available debt facilities and cash

- 2018e Billings of US$66m and 2018e adjusted billings basis EBITDA of US$22m

- Expected to be EPS accretive on a billings basis from the first full year

- 5 Year guidance:

§ 20% growth p.a. in billings/revenues going forward

§ >30% IFRS EBITDA margin by year 5

§ Strong cash conversion / negative working capital

§ ROIC > Group WACC by year 5

 

 

Intertek Group plc ("Intertek" and the "Group"), a Total Quality Assurance provider to a range of industries worldwide, is pleased to announce that it has entered into an agreement to acquire Alchemy Investment Holdings, Inc. ("Alchemy"), an industry leader in People Assurance solutions for the food industry.

 

In a world of increasingly complex supply chains and distribution channels, employees are key in driving operational excellence in multi-site organisations and there is a growing demand for bespoke People Assurance solutions to identify/monitor and efficiently close critical skills gaps amongst frontline employees.

 

Intertek is a global market leader in Assurance solutions, enabling clients to identify and mitigate the intrinsic risk in their operations, supply and distribution chains and quality management systems. The acquisition of Alchemy, a high-growth, high-margin, highly cash-generative, capital-light technology-enabled People Assurance solutions provider, will further strengthen Intertek's global Assurance offering.

 

Alchemy has developed industry-leading content delivered through technology-enabled platforms that provide interactive People Assurance solutions to operations in the food industry. Alchemy's cloud-based software services help clients drive safety, productivity, operational excellence and customer service by monitoring skills gaps within their frontline operations and offering targeted interactive learning solutions.

 

Alchemy's industry-leading content and unique technology platforms are fully scalable within the food industry where Alchemy has 1,100+ clients. Alchemy's solutions are highly relevant across all industries with a large deskless frontline workforce and Intertek will leverage its scale to offer Alchemy's People Assurance solutions to its global client base across multiple business lines and industries outside food.

 

Founded in 2003 and headquartered in Austin, Texas, Alchemy employs approximately 270 people at four locations across the U.S. and Canada. Alchemy is majority owned by the private equity firm The Riverside Company. Alchemy will be acquired for a cash consideration of US$480m on a cash-free and debt-free basis.

 

Transaction highlights:

· Acquisition of an industry-leader, offering technology-enabled People Assurance SaaS (Software-as-a-Solution) that expands Intertek's global Assurance offering with bespoke People Assurance services

 

· Exposure to the highly attractive food industry where demand for quality assurance solutions is constantly growing, driven by increasing regulation and end-customer expectations

 

· Attractive subscription-based revenue model and the majority of Alchemy's customer contracts are 3-year contracts and Alchemy has a track record of high client retention rates

 

· Industry-leading People Assurance platform with broad-based learning content and strong technology platforms that are fully scalable

 

· Strong commercial synergies with Intertek's existing presence in the food supply chain globally as well as across Intertek's business lines in over 100 countries

 

· Alchemy's management team will remain with the business

 

Financial highlights: 

· Alchemy has a strong growth track record and operates a highly attractive business model: high growth, high margin, strong cash-conversion, capital-light and scalable

 

· Alchemy expects to record Billings of US$66m, adjusted Billings EBITDA of US$22m (33.0% margin) for the 12 months ending on 31 December 2018

 

· Annualised organic Billings growth of c.17% between 2016-2018e

 

· Intertek will finance the acquisition using available debt facilities and cash

 

· Intertek expects the acquisition to deliver attractive returns to shareholders and to be EPS accretive on a Billings basis in the first full year after acquisition

 

· 5 Year Guidance:

- 20% growth p.a. in billings/revenues going forward

- >30% IFRS EBITDA margin by year 5

- >25% IFRS EBIT margin by year 5

- Strong cash conversion; negative working capital

- ROIC > Group WACC by year 5

 

· The transaction is subject to customary closing conditions and is expected to be completed in Q3 2018

 

· Due to its subscription-based revenue model, which provides good revenue visibility, Alchemy manages its business on a billings basis. In its 2018 annual report, Intertek will report Alchemy's results in accordance with IFRS and noting that IFRS fair value purchase accounting requires us to revalue Alchemy's acquired deferred revenue balance

 

André Lacroix, Chief Executive Officer of Intertek, commented: 

 

"Intertek Total Quality Assurance (TQA) provides a superior service to our clients through our end-to-end systemic Assurance, Testing, Inspection and Certification (ATIC) solutions. With the acquisition of Alchemy, we are continuing to strengthen our TQA value proposition with the expansion of our Assurance business into People Assurance, helping to provide our clients with a higher level of quality assurance and with greater peace of mind.

 

Intertek's growth in Assurance services has predominantly been focussed on assuring the quality of clients' systems and operating procedures. Alchemy provides us with the opportunity to expand and broaden our Assurance offering towards the assurance of employee skills across our clients' organisations.

 

As corporations around the world increase their focus on quality, safety, productivity and compliance, closing skills-gaps to deliver only the highest customer service standards has become mission critical for clients. Alchemy's unique tailored learning software helps to close the loop, identifying and plugging these gaps quickly and efficiently.

 

Alchemy is a high-quality business with scalable solutions that can be rolled out across many different industries and geographies. This will further accelerate the growth momentum of our capital light and high margin Assurance Business.

 

We are delighted to welcome Alchemy and its strong management team to Intertek."

 

 

- ENDS -

 

Video

A video describing how we are continuing to strengthen and differentiate our TQA value proposition with the expansion of our global Assurance business into People Assurance can be viewed at http://www.intertek.com/investors/

Webcast

A live webcast for analysts and investors will be held today at 7.45am UK time; +44 (0) 20 3003 2666 (Link to webcast). Details can also be found at http://www.intertek.com/investors/ together with a pdf copy of this report. A recording of the audiocast will be available later in the day.

 

Contacts

For further information please contact:

Denis Moreau, Investor RelationsTelephone: +44 (0) 20 7396 3415 investor@intertek.com

Jonathon Brill, FTI ConsultingTelephone: +44 (0) 20 3727 1000 intertek@fticonsulting.com

 

About Intertek

Total Quality. Assured.

Intertek is a leading Total Quality Assurance provider to industries worldwide.

Our network of more than 1,000 laboratories and offices and over 42,000 people in more than 100 countries, delivers innovative and bespoke Assurance, Testing, Inspection and Certification solutions for our customers' operations and supply chains.

Intertek Total Quality Assurance expertise, delivered consistently, with precision, pace and passion, enabling our customers to power ahead safely.

intertek.com

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
ACQEADPAEFAPEAF
Date   Source Headline
22nd Mar 20249:00 amRNSAnnual Financial Report
14th Mar 20241:00 pmRNSDirector/PDMR Shareholding
14th Mar 20241:00 pmRNSDirector/PDMR Shareholding
13th Mar 20241:00 pmRNSDirector/PDMR Shareholding
5th Mar 20247:00 amRNSFinal Results
4th Mar 20247:00 amRNSAcquisition
1st Mar 20241:00 pmRNSDirectorate Change
28th Feb 20241:00 pmRNSDirector/PDMR Shareholding
23rd Nov 20237:00 amRNSTrading Statement
22nd Nov 20231:00 pmRNSBlock listing Interim Review
14th Sep 20231:00 pmRNSDirector Declaration
24th Aug 20237:00 amRNSAcquisition
28th Jul 20237:00 amRNSHalf-year Report
12th Jul 202310:00 amRNSDirectorate Change
7th Jun 20231:00 pmRNSDirector/PDMR Shareholding
31st May 20231:00 pmRNSDirector/PDMR Shareholding
30th May 20233:00 pmRNSHolding(s) in Company
30th May 20231:00 pmRNSBlock listing Interim Review
24th May 202311:00 amRNSResult of AGM
24th May 20237:00 amRNSTrading Statement
3rd May 20237:00 amRNSCapital Markets Event
27th Apr 20234:00 pmRNSDirector Declaration
26th Apr 20234:30 pmRNSDirector Declaration
20th Apr 20234:00 pmRNSDirector Declaration
3rd Apr 20237:00 amRNSAcquisition
24th Mar 20239:00 amRNSNotice of 2023 AGM
21st Mar 20239:00 amRNSAnnual Financial Report
20th Mar 20237:00 amRNSDirectorate Change
14th Mar 20233:00 pmRNSDirector/PDMR Shareholding
14th Mar 20233:00 pmRNSDirector/PDMR Shareholding
14th Mar 20233:00 pmRNSDirector/PDMR Shareholding
28th Feb 20237:00 amRNSFinal Results
23rd Dec 202210:00 amRNSDirectorate Change
13th Dec 202211:00 amRNSDirector Declaration
12th Dec 20221:00 pmRNSDirector Declaration
24th Nov 20227:00 amRNSTrading Statement
21st Nov 20221:00 pmRNSBlock listing Interim Review
2nd Aug 20229:00 amRNSDirector/PDMR Shareholding
29th Jul 20227:01 amRNSAcquisition
29th Jul 20227:00 amRNSHalf-year Report
21st Jun 20221:00 pmRNSDirector/PDMR Shareholding
26th May 20227:00 amRNSDirectorate Change
25th May 202211:00 amRNSResult of AGM
25th May 20227:00 amRNSTrading Statement
23rd May 20221:00 pmRNSBlock listing Interim Review
4th Apr 20223:00 pmRNSDirector/PDMR Shareholding
22nd Mar 20221:00 pmRNSDirector/PDMR Shareholding
22nd Mar 20221:00 pmRNSDirector/PDMR Shareholding
18th Mar 20229:00 amRNSAnnual Financial Report
14th Mar 20221:00 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.